Male breast cancer: thirteen years experience of a single center
Sami Akbulut¹, Ilker Arer¹, Alper Kocbiyik², Mahmut Can Yağmurdur¹, Hamdi Karakayalı¹ and Mehmet Haberal*¹

Address: ¹Department of Surgery, University Hospital of Baskent, Ankara 06490, Turkey and ²Department of Pathology, University Hospital of Baskent, Ankara 06490, Turkey
Email: Sami Akbulut - akbulutsami@gmail.com; Ilker Arer - igy1981@yahoo.com; Alper Kocbiyik - alperkocbiyik@gmail.com; Mahmut Can Yağmurdur - mcyagmurdur@gmail.com; Hamdi Karakayalı - drhamdi@baskent-ank.edu.tr; Mehmet Haberal* - rektorluk@baskent.edu.tr
* Corresponding author

Abstract

Background: This retrospective study analysed the epidemiological, clinical, and therapeutic profiles of breast cancer in males.

Methods: We report our experience at the Hospital of the University of Baskent, where 20 cases of male breast cancer were observed and treated between 1995–2008.

Results: Median age at presentation was 66.7 ± 10.9 years. Average follow-up was 63 ± 18.5 months. The main presenting symptom was a mass in 65% of cases (13 patients). Invasive ductal carcinoma was the most frequent pathologic type (70% of cases).

Conclusion: Male breast cancer patients have an incidence of prostate cancer higher than would be predicted in the general population. Cause of men have a higher rate of ER positivity the responses with hormonal agents are good.

Background

Male breast cancer (MBC) is infrequent; it accounts for 0.8% of all breast cancers, less than 1% of all newly diagnosed male cancers, and 0.2% of male cancer deaths. The median age at diagnosis is 68 years, 5 years older than in women. [1-4].

The aim of this retrospective study was to present our results and analyse the epidemiological, clinical, and therapeutic profiles of this disease in 20 cases treated in our unit between 1995 and 2008.

Patients and methods

Twenty male patients with breast cancer were treated at our University between 1995 – 2008. median age at presentation was 66.7 ± 10.9 years (range 56–90 years).

Results

Two cases the disease was diagnosed incidentally after CT scan of the thorax for other conditions. In three cases, prostate cancer was coincident, renal cell cancer was present in one case. The disease developed after renal transplantation in one case, Kaposi sarcoma in one case. There was a family history of breast cancer in two cases.
Fourteen patients (70%) had a left-sided breast cancer and six patients (30%) had a right-sided tumour. The median follow-up was 63 ± 18.5 months (range: 4–149 months).

Three patients developed local recurrence (Chest wall in one patient, axillary lymph nodes in two patients).

The presenting clinical symptom was a mass in 13 of cases. Pain was the second complaint in 4 of cases. The tumour associated with breast ulceration in 2 of cases and a bloody nipple discharge in one of cases (graphic 1). Upper outer quadrant masses were present in 80% of cases, a retroareolar mass in 10%, and inner quadrants mass in 10%.

Bone pain was observed in one patient, related to presence of metastases. The diagnosis was confirmed by excisional biopsy in 75% cases and tru-cut biopsy in 25% cases.

The type of surgical procedure and tumors size was showed in Figure 1 and 2.

Pathological analysis of the specimens revealed infiltrating ductal carcinoma (IDC) in 70% (14 cases), which one of has mucinous carcinoma together, ductal carcinoma in situ (DCIS) in 25% (5 cases), and one case of coexistent apocrine carcinoma and micropapillary carcinoma [5]. One of the IDC was associated with primary unknown adenocarcinoma. Pathological characteristics were showed in Figure 3

Lymph node involvement
Axillary lymph nodes contained metastasis in 6 of the cases. Five of 6 cases had more than four lymph nodes involved. One of 6 cases had nipple areola complex invasion. Four of cases had positive lymph nodes with extracapsular extension.

Hormone receptors
Fourteen cases had 30% to 100% positive estrogen, progesterone receptors. Three case had only positive estrogen receptor. In three patients examination of hormone reperete was not done

Because the operations of these 3 patients was done between 1995–1998 and at that years receptor scanning was not been performed routinely.

Examination of c-erb-2 oncoprotein was done in 15 patients. There was not any staining with c-erb b2 except one case who has apocrin carcinoma.

Treatment
Adjuvant radiation therapy with an average dose of 50 Gy was given to all of the patients who had axillary lymph node metastasis and to whom performed breast sparing surgery. In addition, tamoxifen therapy was also given if the hormone receptors were positive.

Only hormonal therapy was given in one case who had an apocrine carcinoma, and had 80% positive hormone receptor and categorized as T2N0M0.

Adjuvant radiation therapy, chemotherapy and hormonal therapy was given in patient(T2N0M0) who had IDC and
mucinous carcinoma together and in patient who had a chest wall invasion.

**Outcome**

After the first therapy protocole the patients were taken to a 6 month follow-up. Only 2 cases, the cases with bone and lung metastasis, were lost. Of the cases with extracapsular invasion two of them and n the patient with T4 tumour (in the chest wall) showed local recurrence. Radio- and chemotheraphy were given to these cases with a difference of excision addition to the chest wall recurrence. At the end of the six month all recurrences regress reduced totally. All of the alive 18 cases came to the control in the last year. The doses of agents placed in the therapy protocole of immunosuppressive patients, were reduced to minimum. None of them shows pathological evidence belong to metastasis or local invasion.

**Discussion**

MBC is an uncommon disease, which presents mostly in the latter decades of life. It represents less than 1% of all malignancies in men and is responsible for 0.1% of male cancer deaths [2]. It behaves similar to female breast cancer in most cases [6]. In our clinic incidence ratio is 2, 9:100 which is more than literature [7].

Men have a higher rate of ER positivity, which accounts for good responses with hormonal agents as in our study. We used only tamoxifen in all ER positive, DCIS cases. We used tamoxifen combined with radiotherapy in ER positive, IDC cases. The prevalence of MBC increases with age, with a mean age of 60–65 years at presentation [8]. Risk factors include increasing age, radiation exposure, and factors related to abnormalities in estrogen and androgen balance, including testicular disease, infertility, obesity, and cirrhosis. Risk factors related to a genetic predisposition include Klinefelter’s syndrome, family history, and BRCA gene mutations, particularly BRCA2 mutations. Gynecomastia is not a risk factor [9].

Male breast cancer patients have an incidence of prostate cancer higher than would be predicted in the general population; this risk factor has implications for prostate cancer screening. In a recent study of Lee UJ et al, 12 of 69(17%) patients with male breast cancer also had a diagnosis of prostate cancer [10]. In our study 3 of 20(15%) patients had breast cancer with prostate cancer.

Breast cancer occurred in two patients with immunosuppressive disorders in our series.

MBC is usually diagnosed at an advanced stage, with a typical subareolar mass associated with axillary lymph nodes and pain [11,12].

The male breast contains only ductal tissue, hence, most MBCs are of the ductal type. Histologically, 90% of male breast cancers are invasive ductal carcinomas. Approximately 80% are ER positive, 75% are PR positive, and 35% overexpress HER-2/neu. The remaining 10% are DCIS. Given the absence of terminal lobules in the normal male breast, lobular carcinoma, both invasive and in situ, is rarely seen [3,4].

The most common surgical treatment is modified radical mastectomy with axillary node dissection. Adjuvant radiotherapy has an important role in reducing the risk of local recurrence in large tumors, lymph node and muscle involvement [13]. Tamoxifen is the most widely used adjuvant therapy, because it improves survival. It may be associated with more limited side effects in men than in women, like decreased libido, weight gain, hot flushes, mood alterations, depression, insomnia and deep vein thrombosis. There is no evidence that chemotherapy improves long term survival. Chemotherapy may be useful in node positive and locally advanced disease. The use of adjuvant RT has not been conclusively proven to reduce local recurrence.

Prognostic factors in male breast cancer are the same as in female breast cancer and include nodal involvement,
tumor size, histologic grade, and hormone receptor status. When matched for age and stage, survival is similar to that in women. Poor prognosis is attributed to old age, axillary lymph node metastases (>4) and negative hormone receptors [13,14].

**Competing interests**

We confirm, none of the authors listed in this manuscript have any financial or other conflicts of interest to disclose.

**Authors’ contributions**

SA, MCY and HK contributed writing the article and review of the literature as well as undertaking a comprehensive literature search; SA and IA contributed design and manuscript preparation; AK provided the histopathological information.

**Acknowledgements**

This work was performed in University Hospital of Baskent, Ankara, Turkey. The authors wish to thank Prof Dr Mehmet Haberal (President of Baskent University) for supporting this work.

**References**

1. English JC, Middleton C, Patterson JW, Slingluff CL: Cancer of the male breast. J Dermatol 2000, 39(12):881-6.
2. El Omari-Alaoui H, Lahdiri I, Nejar I, Hadadi K, Ahyoud F, Hachi H, Alhilal M, Errihani H, Benjaafar N, Souadka A, El Gueddari BK: Male breast cancer. A report of 71 cases. Cancer Radiother 2002, 6(6):349-351.
3. Lantitis S, Rice Aj, Vaughan A, Cathcart P, Filippakis G, Mufti RA, Hadjiminas Dj: Diagnosis and management of Male Breast Cancer. World Journal of Surgery 2008, 32(11):2471-6.
4. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KL, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Brown GP: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report. J Clin Oncol 2002, 20(15):3317-27.
5. Liberian L, Bracero N, Vuolo MA, Dershaw DD, Morris EA, Abramson AF, Rosen PP: Percutaneous large-core biopsy of papillary breast lesions. AJR Am J Roentgenol 1999, 172(2):331-7.
6. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H: Male breast cancer: is the scenario changing. World J Surg Oncol 2008, 6:58.
7. El Hajjam M, Khaiz D, Benider A, Lakhloufi A, Abi F, Kahlain A, Bouzidi A: Cancer of the breast in men. Apropos of 50 cases. J Chir (Paris) 1995, 132(3):131-6.
8. Hermann K, Lobaziewicz W, Skotnicki P, Fortuna J, Kury T, Ledziak T: Male breast cancer. Does the prognosis differ compared to female? Neoplasma 2000, 47(3):191-5.
9. Tajima N, Tsukuma H, Oshima: Descriptive epidemiology of male breast cancer in Osaka, Japan. J Epidemiol 2001, 11(1):1-7.
10. Lee UJ, Jones JS: Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening. Prostate Cancer Prostatic Dis 2008 in press.
11. Winchester Dj: Male breast carcinoma: a multinstitutional challenge. Cancer 1998, 83(3):399-400.
12. Donegan WL, Redlich PN, Lang PJ, Gali MT: Carcinoma of the breast. A multinstitutional survey. Cancer 1999, 83(3):498-509.
13. Stranzl H, Mayer R, Quehenberger F, Prettenhofer U, Wiltfurch P, Stöger H, Hackl A: Adjuvant radiotherapy in male breast cancer. Radiology and Oncology 1999, 53(1):29-35.
14. Vetto J, Jun SY, Padduch D, Eppich H, Shih R: Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg 1999, 177(5):379-83.